C
에스엘에스바이오
246250KOSDAQ44.5 / 100
Reference Date: 2026-09-09
Financial Score12.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
SLS Bio, established in 2007, specializes in pharmaceutical quality control, new drug development support, and in vitro diagnostic equipment. The company contributes to the pharmaceutical industry's advancement and public healthcare benefits through drug quality testing, generic drug promotion, and new drug development assistance.
Number of Employees
63people
Average Salary
35.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
3.96Industry Average 1.200.0Point
3.3x industry avg (risky)
ROE
-48.68Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
26.32Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼29.8% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼799.7% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -10.6% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position4.0Point
52w mid range (50%)
Current 1,969Won52-week high 1,96952-week low 1,969
1-month return3.0Point
1m 0% (flat)
Volume trend3.0Point
Volume flat
Detailed Disclosure
2 totalPositive 0Neutral 2Negative 0
- Neutral기타시장안내 (개선기간 종료에 따른 상장폐지 여부 결정 안내)2026-08-31
- Neutral반기보고서 (2026.06)2026-08-14